We join the Global Alzheimer's Platform Foundation's (GAP) Chief Commercial Officer, Lammert Albers, hosted a webinar with OurChief Scientific Officer, Robin Wolz, and Fujirebio's Director of Clinical Research and Development, Rachel Radwan, on the importance of collaboration in advancing AD clinical trials with the joint use of Blood-Based Biomarkers and Amyloid PET imaging.
